| P50 | author | Leylagul Kaynar | Q41104793 |
| P2093 | author name string | Fatih Demirkan | |
| | Mehmet Ali Erkurt | |
| | Hakan Özdoğu | |
| | Emre Tekgündüz | |
| | Filiz Vural | |
| | Mutlu Arat | |
| | Hakan Göker | |
| | Fevzi Altuntaş | |
| | İlhami Kiki | |
| | Seçkin Çağırgan | |
| | Turkish Society of Apheresis (TSA) | |
| P2860 | cites work | Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title) | Q26782868 |
| | Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients | Q34454624 |
| | Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant | Q35192785 |
| | Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. | Q36428104 |
| | Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation | Q36794295 |
| | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group | Q37037265 |
| | Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations | Q38154080 |
| | Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. | Q38200909 |
| | Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation | Q38210890 |
| | Use of laboratory tests to guide initiation of autologous hematopoietic progenitor cell collection by apheresis: results from the multicenter hematopoietic progenitor cell collection by Apheresis Laboratory Trigger Survey | Q38259749 |
| | Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. | Q38387292 |
| | Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma | Q38707629 |
| | How do we mobilize and collect autologous peripheral blood stem cells? | Q38978669 |
| | Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients | Q39900044 |
| | Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia | Q40328857 |
| | Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial | Q40490106 |
| | Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation | Q40880138 |
| | Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study | Q41003137 |
| | Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario | Q42380588 |
| | Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo | Q42592824 |
| | Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio | Q43282877 |
| | Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment | Q43888363 |
| | Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell tr | Q44772922 |
| | Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma | Q46052750 |
| | A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. | Q48281446 |
| | Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma. | Q48337454 |
| | The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experi | Q51049109 |
| | A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. | Q51135328 |
| | Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. | Q53083681 |
| | Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. | Q53426777 |
| | Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. | Q54582789 |
| | Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients | Q61971228 |
| | A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients | Q73895207 |
| | Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics | Q83861540 |
| | A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor | Q84496846 |
| | Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation | Q84931074 |
| | PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization | Q88008635 |
| P433 | issue | 6 | |
| P304 | page(s) | 845-849 | |
| P577 | publication date | 2017-11-10 | |
| P1433 | published in | Transfusion and Apheresis Science | Q15758507 |
| P1476 | title | Autologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: A position-statement from the Turkish Society of Apheresis (TSA) | |
| P478 | volume | 56 | |